Fountainheadinvesting

Fountainhead Investing

  • Objective Analysis: Research On High Quality Companies With Sustainable Moats
  • Tech Focused: 60% Allocated To AI, Semiconductors, Technology

5 Star Tech Analyst Focused On Excellent Companies With Sustainable Moats

Categories
Enterprise Software Stocks

Palantir (PLTR) Earnings Beat Expectations: A Strong Quarter Amidst Stock Decline

Palantir (PLTR) Post Market down 6% but solid earnings and revenue beat and improved guidance.

Rev – $634Mn up 21% beats $615Mn consensus

Adjusted Operating income $226Mn beats forecast of $196-$200Mn

For the full year, Palantir lifted its revenue guidance to between $2.677 billion and $2.689 billion, above the previous range of $2.652 billion to $2.668 billion

Adjusted EPS – $0.08 per share in line with estimates

Palantir PLTR 8.06% followed up its “bombastic” December quarter with even better results for the March quarter as the data analytics software company continued to gain traction with its artificial intelligence tools in particular with U.S. commercial customers.

Nonetheless, the stock is losing ground following the announcement. Palantir shares, which rallied 8.1% in Monday’s regular session, was off more than 7% in late trading, leaving the stock up slightly from Friday’s close. The stock was up 47% this year as of Monday’s closing bell.

For the March quarter, Palantir posted revenue of $634 million, up 21% from a year ago, and ahead of both the company’s guidance range of $612 million to $616 million and Wall Street’s consensus of $615 million as tracked by FactSet.

Adjusted operating income was $226 million, well ahead of Palantir’s forecast of $196 million to $200 million. Adjusted profit was 8 cents a share, in line with Street estimates. Under generally accepted accounting principles, the company earned 4 cents a share.

Palantir gained impressive traction with U.S. commercial customers. That segment of the business grew 40% from a year ago and 14% sequentially to $150 million. Overall, commercial business was $299 million, up 27% and ahead of consensus at $292 million. Palantir said that the U.S. commercial business grew 69% year over year if you back out the contribution from customers where Palantir had made strategic investments a few years ago in a now-suspended program tied to SPAC-related IPOs.

Palantir said “remaining deal value” for U.S. commercial customers grew 74% from a year earlier and 14% sequentially. The total number of signed deals in the quarter increased 52% year over year for the quarter overall, including a 94% increase in U.S. commercial deals, Palantir reported.

Meanwhile, government segment revenue was $335 million, up 16% from a year ago, ahead of consensus at $322 million, and an acceleration from 11% growth in the December quarter.

“America is adopting technology and especially AI in a way no other part of the world is,” CEO Alex Karp said in an interview with Barron’s. “We are the only company providing the right infrastructure to make LLMs [large language models] actually valuable,” noting that the company is adopting a tagline of “beyond chat” for its AI business.

“We have a vibrancy of our tech and corporate scene that no one else has,” he said. “And as important as it is for Palantir, it’s going to change the GDP trajectory of America.” In the long run, he said the strongest players in AI will be in the U.S. and Middle East, with Europe “closing its eyes and hoping the nightmare will end.”

Palantir also provided strong guidance. For the June quarter, the company sees revenue of between $649 million and $653 million, ahead of consensus at $643 million, with adjusted operating income of between $209 million and $213 million, above the Street at $201 million.

For the full year, Palantir lifted its revenue guidance to between $2.677 billion and $2.689 billion, above the previous range of $2.652 billion to $2.668 billion. The company now sees U.S. commercial business for the year of above $661 million, up at least 45%; the previous guidance had called for 40% growth in that segment. Palantir also boosted its adjusted operating income guidance to between $868 million and $880 million from a previous forecast of $834 million to $850 million.

Categories
Networking Stocks

Arista Networks Posts Strong Earnings: A HOLD for Now

Arista Networks (ANET) $275 post earnings, HOLD

Beats all around and guidance is raised as well.

For the period ending March 31, Arista earned an adjusted $1.99 per share as revenue rose 16.3% year-over-year to $1.57B.

A consensus of analysts expected the company to earn $1.74 per share on $1.55B in revenue.

Looking ahead, Arista Networks expects to generate sales between $1.62B and $1.65B, compared to estimates of $1.62B.

Adjusted gross margin is forecast to be around 64% while adjusted operating margin is expected to be around 44%.

Arista also said that it has finished its previous $2B share buyback program and its board of directors has approved an additional program to repurchase up to $1.2B worth of shares.

Arista’s biggest clients Meta and Microsoft are ramping up Datacenter buildouts so Arista should remain strong. Excellent company, but has been expensive for the past 6 months, holding for now, and will re-assess if the price falls.

Categories
Stocks

Novo Nordisk (NVO) Q1 Earnings: Strong Sales Growth and Raised Guidance Amidst Pricing Pressures

Novo Nordisk (NVO) $126 Maintaining Buy Recommendation.

No surprise, Novo too, increased its outlook like its competitor Eli Lilly.

Increased full-year outlook on the back of strong Q1 results, driven by increased demand for its GLP-1-based diabetes and weight-loss drugs Ozempic and Wegovy.

Q1- Blockbuster sales double The Danish drugmaker’s total Q1 revenue jumped 22% Y/Y to DKK 65.35B ($9.39B), as sales of its blockbuster drugs surged: Wegovy sales more than doubled to DKK 9.38B ($1.35B); Ozempic sales grew 43% in constant currency to DKK 27.81B (~$4B).

Novo (NVO) now expects sales growth of 19%-27% in constant currency this year, slightly higher than its prior guidance of 18%-26% growth. Operating profit growth is projected to be 22%-30% in constant currency, compared to its earlier forecast of 21%-29%.

The raised guidance reflects the expected volume growth of its diabetes and obesity drugs, both in the U.S. and internationally, although pricing pressures are expected to continue.

The company also continues to see supply constraints and resulting GLP-1 drug shortages and is spending in internal and external capacity to boost supplies.

Pricing pressure – Despite the upbeat outlook, Novo (NVO) fell 3% in early U.S. premarket trade on Thursday. To note, the stock has gained close to 25% so far this year. 

Novo Nordisk CFO Karsten Munk Knudsen said on a conference call with reporters that prices of the products were “slightly down” last quarter and that the company expects them to continue to decline this year, according to Reuters.

Novo (NVO) faces stiff competition in the weight-loss drug market from Eli Lilly (LLY), which has also seen surging demand for its GLP-1 drugs Zepbound and Mounjaro.

Categories
AI Stocks

Apple (AAPL) Q2 Earnings: Resilient Margins Amidst Sales Decline

Apple (AAPL)

China sales are only 8% lower – this is better than expectations.

Japan and the rest of Asia-Pacific were much lower at 13% and 17% respectively.

iPhone sales down 10.4% – this could have been worse.

Services of course the biggest growth category with 14% growth.

The interesting thing here is that even as Apple keeps contracting in its product categories, margins get better with the higher margin services taking more share of the pie. Operating income dropped only 1.5% compared to the 4% revenue drop.

Apple (AAPL) $179 post-market, from $173.

  • Apple press release (NASDAQ: AAPL): Q2 GAAP EPS of $1.53 beats by $0.03.
  • Revenue of $90.8B (-4.3% Y/Y) beats by $190M.
  • Shares +2.4%.
  • Apple’s board of directors has declared a cash dividend of $0.25 per share of the Company’s common stock, an increase of 4 percent. The dividend is payable on May 16, 2024, to shareholders of record as of the close of business on May 13, 2024. The board of directors has also authorized an additional program to repurchase up to $110 billion of the Company’s common stock.
Categories
Semiconductors Stocks

Qualcomm (QCOM) Q2 Earnings: Strong Results and Guidance Boost Shares 4.5%

Qualcomm (QCOM) Maintaining Buy on Declines

Qualcomm (NASDAQ: QCOM) shares rose 4.5% in extended trading on Wednesday after the San Diego-based semiconductor firm offered up better-than-expected guidance on top of strong second-quarter results.

Auto is the big mover with a 35% increase in revenues. I’m also surprised that handsets held up considering Apple’s weakness.

Looking to the third quarter, Qualcomm said it expects to earn between $2.15 and $2.35 per share on an adjusted basis, with revenue forecast between $8.8B and $9.6B.

Analysts were expecting $2.16 per share in earnings and $9.05B in revenue.

For the period ending March 24, Qualcomm earned an adjusted $2.44 per share on $9.39B in revenue, as QCT sales rose 1% year-over-year to $8.02B. Revenue from handsets rose 1% year-over-year to $6.18B while automotive sales jumped 35% to $603M. Sales from (Internet of Things) IoT tumbled 11% to $1.243B.

Licensing revenue rose 2% year-over-year to $1.318B.

A consensus of analysts expected the company to earn $2.32 per share on $9.35B in revenue.

“We are pleased to report strong quarterly results, with EPS exceeding the high end of our guidance,” said Cristiano Amon, President and CEO of Qualcomm Incorporated. “We are excited about our continued growth and diversification, including achieving our third consecutive quarter of record QCT Automotive revenues, upcoming launches with our Snapdragon X platforms, and enabling leading on-device AI capabilities across multiple product categories.”

Categories
Stocks

Eli Lilly Q1 Earnings: Strong EPS Beat and Raised 2024 Guidance Amid Soaring Demand for Obesity Drugs

Eli Lilly (LLY) $790 Pre-Market – Up 6% – We’ve had a Buy on it and will continue to add on declines.

Lilly posted great results, but more importantly raised 2024 guidance by $2Bn (5-6%), leading to the pre-market jump! Obesity drugs have a huge demand, which they’re struggling to fill.

Eli Lilly press release (NYSE: LLY): Q1 Non-GAAP EPS of $2.58 beats by $0.09.

Revenue of $8.77B (+26.0% Y/Y) misses by $160M.

Revenue in Q1 2024 increased by 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance.

2024 full-year revenue guidance raised by $2.0 billion; reported EPS guidance raised $1.25 to be in the range of $13.05 to $13.55 and non-GAAP EPS guidance raised $1.30 to be in the range of $13.50 to $14.00 vs $12.46 Consensus.

Categories
Stocks

PayPal Q1 Earnings: Revenue Beat and Optimistic Outlook Despite Market Challenges

Paypal (PYPL) $70 Pre-Market up 7%.

Maintaining Buy, at this price there’s little downside and Paypal seems to be walking the talk with steady increases in revenue in an overcrowded market. Paypal is a mature company and getting 12-15% a year is pretty good.

Q1 revenue of $7.70B, topping the $7.52B consensus, fell from $8.03B in Q4 2023 and grew from $7.04B in Q1 2023.

Q1 Non-GAAP EPS of $1.40 beats by $0.18.

Guidance

Non-GAAP earnings per diluted share are expected to increase by a mid-to-high single-digit percentage compared to $3.83 (based on the new non-GAAP methodology) in the prior year.2024 is a transition year, righting a ship that had screwed up quite badly for the past three years and I think they should be able to do a decent job. 

Categories
Stocks

AMD Q1 Results: Strong Data Center Growth Amid Challenges in Gaming and Embedded Segments

AMD Quarterly Result

The Datacenter and client segments did well.

AMD’s struggles outside the Datacenter continue with gaming and embedded segments still dealing with inventory digestion, but they did come in within estimates and kept guidance in line with the previous one. 

Source: Seeking Alpha

  • Advanced Micro Devices press release (NASDAQ: AMD): Q1 Non-GAAP EPS of $0.62 beats by $0.01.
  • Revenue of $5.47B (+2.2% Y/Y) beats by $20M.
  • Record Data Center segment revenue of $2.3 billion was up 80% year-over-year driven by growth in both AMD Instinct™ GPUs and 4th Gen AMD EPYC™ CPUs. Revenue increased 2% sequentially driven by the first full quarter of AMD Instinct GPU sales, partially offset by a seasonal decline in server CPU sales.
  • Client segment revenue was $1.4 billion, up 85% year-over-year driven primarily by AMD Ryzen™ 8000 Series processor sales. Revenue decreased 6% sequentially.
  • Gaming segment revenue was $922 million, down 48% year-over-year and 33% sequentially due to a decrease in semi-custom revenue and lower AMD Radeon™ GPU sales.
  • Embedded segment revenue was $846 million, down 46% year-over-year and 20% sequentially as customers continued to manage their inventory levels.
  • For the second quarter of 2024, AMD expects revenue to be approximately $5.7 billion, plus or minus $300 million vs. $5.69B consensus. At the mid-point of the revenue range, this represents year-over-year growth of approximately 6% and sequential growth of approximately 4%. Non-GAAP gross margin is expected to be approximately 53%.

The stock is down 3% to $153, after dropping 1% to $158 during market hours.

Categories
Stocks

Tesla Surges 14% on FSD Approval in China: Key Win for EV Giant Amidst Rising Competition

Tesla (TSLA) $193 up 14%

Good news for Tesla – Musk’s China visit seems to have paid off. The markets and the street love it and it’s great for those of you who had the patience to hold on to it. 

One of the key reasons for the approval seems to be the collaboration with Baidu, plus China was very keen for a win. Nonetheless, this is good for the market. Two heavyweights Apple and Tesla are seeing support.

Read on from Barron’s today.

https://www.barrons.com/articles/tesla-stock-price-news-china-elon-musk-8476fa2e?mod=BRNS_ENG_NAS_EML_BULLETIN_AUTO_NAH

Tesla Stock Soars on FSD Approval in China. 

3 Reasons the News Is a Big Deal.

According to Barrons “The win does a few things for Tesla. For starters, better driver-assistance products can mean more demand for Tesla vehicles in China. Second, it demonstrates the company can navigate complicated government regulations related to driver-assistance technology. And third, it shows that Tesla has increasing confidence in the quality of its self-driving car technology.”

“We expect this announcement to lead to a near-term uptick in FSD attach rates—which we currently model at about 10%—and improve the offering longer-term,” wrote Baird analyst Ben Kallo in a Monday report. Attach rates refer to how many people buying Tesla vehicles also buy FSD. “We also view this announcement as a potential pathway for Tesla to follow for entering new markets.”

“While the long-term valuation story at Tesla hinges on FSD and autonomous, a key missing piece in that puzzle is Tesla making FSD available in China which is now a done deal,” added Ives. “This is a key moment for Musk as well as Beijing at a time that Tesla has faced massive domestic EV competition in China along with softer demand.”

To help win Chinese approval for FSD, Musk needed to assuage regulators’ concerns about data security risks. To that end, he agreed to use navigation and mapping functions provided by Chinese firm Baidu BIDU 5.77%, the Journal said.

Baidu’s American depositary receipts, or ADRs, were up 4.1% in early trading at $104.65 apiece.